<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616573</url>
  </required_header>
  <id_info>
    <org_study_id>07024</org_study_id>
    <nct_id>NCT04616573</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-center, Randomized, Masked, Controlled, Post-market Study Of Use Of The OMNI® Surgical System In Combination With Cataract Extraction In Open Angle Glaucoma (VERITA)</brief_title>
  <official_title>A Prospective, Multi-center, Randomized, Masked, Controlled, Post-market Study Of Use Of The OMNI® Surgical System In Combination With Cataract Extraction In Open Angle Glaucoma (VERITA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sight Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sight Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First, to prospectively compare the clinical effect of the transluminal viscoelastic delivery&#xD;
      and trabeculotomy using the OMNI Surgical System to the iStent Inject used with Cataract&#xD;
      Extraction in eyes with open angle glaucoma (OAG) and second, to prospectively compare the&#xD;
      clinical effect of the transluminal viscoelastic delivery using the OMNI Surgical System to&#xD;
      the iStent Inject used with Cataract Extraction in eyes with open angle glaucoma (OAG)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Sponsor decision&#xD;
  </why_stopped>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in unmedicated DIOP from baseline at 12-month postoperative examination</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ab-interno transluminal viscoelastic delivery using OMNI surgical System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>iStent Inject implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OMNI® Surgical System</intervention_name>
    <description>Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System</description>
    <arm_group_label>Ab-interno transluminal viscoelastic delivery using OMNI surgical System</arm_group_label>
    <arm_group_label>Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent inject</intervention_name>
    <description>Trabecular meshwork implantation</description>
    <arm_group_label>iStent Inject implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, 22 years or older&#xD;
&#xD;
          -  Visually significant cataract&#xD;
&#xD;
          -  Mild to moderate open angle glaucoma&#xD;
&#xD;
          -  On 1-5 IOP-lowering medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following prior treatments for glaucoma:&#xD;
&#xD;
          -  Laser trabeculoplasty ≤3 months prior to baseline&#xD;
&#xD;
          -  Implanted with iStent (All types), Cypass, Xen, Express, glaucoma draining&#xD;
             device/valve, or Hydrus Device&#xD;
&#xD;
          -  Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy, ECP or CPC Acute angle&#xD;
             closure, normal tension, traumatic, congenital, malignant, uveitic, neovascular or&#xD;
             severe glaucoma as documented in subjects' medical record.&#xD;
&#xD;
          -  Concurrent ocular pathology or systemic medical condition which, in the Investigator's&#xD;
             judgment, would either place the subject at increased risk of complications,&#xD;
             contraindicate surgery, place the subject at risk of significant vision loss during&#xD;
             the study period (e.g., wet AMD, corneal edema, Fuch's dystrophy, active intraocular&#xD;
             infection or inflammation within 30 days prior to Screening Visit, etc.), or interfere&#xD;
             with compliance to elements of the study protocol (e.g., returning to Investigator's&#xD;
             office for follow-up visits).&#xD;
&#xD;
          -  Women of childbearing potential if they are currently pregnant or intend to become&#xD;
             pregnant during the study period; are breast-feeding; or are not in agreement to use&#xD;
             adequate birth control methods to prevent pregnancy throughout the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eye Center South</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates and SurgiCenter of Vineland</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

